VPS9D1 anticorps (AbBy Fluor® 680)
Aperçu rapide pour VPS9D1 anticorps (AbBy Fluor® 680) (ABIN4997931)
Antigène
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Réactivité croisée
- Humain, Souris, Rat
-
Purification
- Purified by Protein A.
-
Immunogène
- KLH conjugated synthetic peptide derived from human C16orf7/ATP-BL
-
Isotype
- IgG
-
-
-
-
Indications d'application
- IF(IHC-P) 1:50-200
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Agent conservateur
- ProClin
-
Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Date de péremption
- 12 months
-
-
- VPS9D1 (VPS9 Domain Containing 1 (VPS9D1))
-
Autre désignation
- C16orf7
-
Sujet
-
Synonyms: ATP BL, C16orf7, Chromosome 16 open reading frame 7, CP007_HUMAN, Protein ATP-BL, Uncharacterized protein C16orf7.
Background: Chromosome 16 encodes over 900 genes in approximately 90 million base pairs, makes up nearly 3 % of human cellular DNA and is associated with a variety of genetic disorders. The GAN gene is located on chromosome 16 and, with mutation, may lead to giant axonal neuropathy, a nervous system disorder characterized by increasing malfunction with growth. The rare disorder Rubinstein-Taybi syndrome is also associated with chromosome 16, though through the CREBBP gene which encodes a critical CREB binding protein. Signs of Rubinstein-Taybi include mental retardation and predisposition to tumor growth and white blood cell neoplasias. Crohn's disease is a gastrointestinal inflammatory condition associated with chromosome 16 through the NOD2 gene. An association with systemic lupus erythematosis and a number of other autoimmune disorders with the pericentromeric region of chromosome 16 has led to the identification of SLC5A11 as a potential autoimmune modifier.
Antigène
-